Quality Systems – Page 36

Container closure integrity risk during market launch – documentation gaps regulators question

Assessing Risks to Container Closure Integrity During Market Launch In the pharmaceutical manufacturing sphere, ensuring container closure integrity (CCI) is paramount, especially during the critical phase of market launch. Recent…

PV system audit finding during inspection – preventing repeat PV findings

Addressing PV System Audit Findings During Inspections to Prevent Recurrences Pharmaceutical organizations often face challenges related to audit findings during inspections of their Pharmacovigilance (PV) systems. These findings can signify…

Supplier qualification gap during supplier change – documentation gaps regulators question

Addressing Supplier Qualification Gaps During Supplier Change: An Investigation The pharmaceutical manufacturing industry faces significant challenges when qualifying new suppliers and managing supplier changes. Gaps in documentation can lead to…

PV system audit finding during benefit–risk assessment – CAPA for PV system weaknesses

Understanding and Addressing PV System Audit Findings During Benefit-Risk Assessment Pharmaceutical organizations rely heavily on Pharmacovigilance (PV) systems to ensure drug safety throughout the product lifecycle. Audit findings pertaining to…

Artwork change error during inspection readiness – documentation gaps regulators question

Exploring Artwork Change Errors During Inspection Readiness: A Comprehensive Guide Artwork change errors can significantly impact your pharmaceutical operations, especially when preparing for inspections. These errors often lead to documentation…

Safety signal escalation delay during benefit–risk assessment – how to strengthen benefit–risk documentation

Addressing Delays in Safety Signal Escalation during Benefit-Risk Assessments In the realm of pharmaceutical development and pharmacovigilance, the timely escalation of safety signals is paramount for effective benefit-risk assessment. Delays…

Container closure integrity risk during development – inspection evidence expectations

Addressing Risks Associated with Container Closure Integrity During Development: Inspection and Evidence Requirements In the pharmaceutical industry, ensuring the integrity of container closures is critical during product development. A failure…

Safety signal escalation delay during signal review – inspection questioning scenarios

Addressing Delays in Safety Signal Escalation During Signal Review: Investigative Strategies In the highly regulated pharmaceutical landscape, timely and effective safety signal escalation is crucial to ensure patient safety and…

Container closure integrity risk during inspection readiness – documentation gaps regulators question

Assessing Container Closure Integrity Risks in Pharmaceutical Inspections: Identifying Documentation Gaps Container closure integrity (CCI) is critical for ensuring the safety, efficacy, and quality of pharmaceutical products. During inspection readiness,…

Literature surveillance failure during inspection – inspection questioning scenarios

Addressing Literature Surveillance Failures During Regulatory Inspections During regulatory inspections, pharmaceutical companies may encounter significant challenges related to literature surveillance failures. These failures can manifest through inconsistent data, overlooked literature…

Artwork change error during market launch – regulatory risk analysis and mitigation

Analyzing Artwork Change Errors During Market Launch: Risks and Mitigation Strategies Artwork change errors during product launches present significant regulatory risks, potentially leading to non-compliance with Good Manufacturing Practices (GMP)…

Periodic report inconsistencies during signal review – CAPA for PV system weaknesses

Addressing Inconsistencies in Periodic Reports During Signal Reviews: A Comprehensive CAPA Approach In the realm of pharmacovigilance (PV), periodic report inconsistencies during signal reviews can pose significant challenges to data…